Ascendis Pharma submits TransCon CNP marketing authorization application to EMA

Ascendis Pharma (ASND) announced it has submitted a marketing authorization application to the European Medicines Agency for TransCon CNP as a treatment for children with achondroplasia, a rare genetic condition that causes skeletal dysplasia and, for many affected individuals, significant health, physical functioning, and quality of life impacts. TransCon CNP is an investigational prodrug of C-type natriuretic peptide administered once weekly, designed for continuous inhibition of the overactive FGFR3 pathway in achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.